Our results suggested that the simultaneous activation of multi-RTK (EGFR, ERBB2, ERBB4, MET and/or AXL) in individual ovarian cancer contribute to the drug resistance to individual RTK inhibitors in ovarian cancer. Here, MET is linked to ovarian cancer.